These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33647591)

  • 21. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
    Stellmann JP; Neuhaus A; Lederer C; Daumer M; Heesen C
    PLoS One; 2014; 9(3):e92761. PubMed ID: 24651401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
    Galego O; Gouveia A; Batista S; Moura C; Machado E
    Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and radiological activity of secondary progressive multiple sclerosis in a population-based cohort.
    Mathey G; Ancel T; Garot T; Soudant M; Pittion-Vouyovitch S; Guillemin F; Debouverie M; Epstein J
    Eur J Neurol; 2021 Jul; 28(7):2238-2248. PubMed ID: 33838072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
    Lorscheider J; Kuhle J; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Hupperts R; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Sola P; Ferraro D; Trojano M; Ramo-Tello C; Lechner-Scott J; Pucci E; Solaro C; Slee M; Van Pesch V; Sanchez Menoyo JL; van der Walt A; Butzkueven H; Kappos L; Kalincik T;
    Eur J Neurol; 2019 Feb; 26(2):363-370. PubMed ID: 30298572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.
    Wolinsky JS; Montalban X; Hauser SL; Giovannoni G; Vermersch P; Bernasconi C; Deol-Bhullar G; Garren H; Chin P; Belachew S; Kappos L
    Ann Neurol; 2018 Oct; 84(4):527-536. PubMed ID: 30155979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM).
    Alonso R; Quarracino C; Eizaguirre B; Cohen L; Silva B; Pita C; Rojas JI; Pappolla A; Miguez J; Patrucco L; Cristiano E; Vrech C; Volman G; Silva E; Barboza A; Deri N; Tkachuk V; Zanga G; Tavolini D; Saladino ML; Luetic G; Menichini ML; Carnero Contentti E; López P; Steinberg J; Divi P; Hryb J; Alves Pinheiro A; Carra A; Balbuena ME; Lázaro L; Fernández Liguori N; Garcea O;
    Neurol Sci; 2020 Nov; 41(11):3329-3335. PubMed ID: 32840711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Definitions of primary-progressive multiple sclerosis trajectories by rate of clinical disability progression.
    Achiron A; Dreyer-Alster S; Gurevich M; Menascu S; Magalashvili D; Dolev M; Stern Y; Ziv-Baran T
    Mult Scler Relat Disord; 2021 May; 50():102814. PubMed ID: 33578205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo.
    Absinta M; Sati P; Masuzzo F; Nair G; Sethi V; Kolb H; Ohayon J; Wu T; Cortese ICM; Reich DS
    JAMA Neurol; 2019 Dec; 76(12):1474-1483. PubMed ID: 31403674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Auguste P; Colquitt J; Connock M; Loveman E; Court R; Ciccarelli O; Counsell C; Armoiry X
    Pharmacoeconomics; 2020 Jun; 38(6):527-536. PubMed ID: 32048205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
    Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural history of primary progressive multiple sclerosis.
    Ebers GC
    Mult Scler; 2004 Jun; 10 Suppl 1():S8-13; discussion S13-5. PubMed ID: 15218804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.
    Lincoln NB; Bradshaw LE; Constantinescu CS; Day F; Drummond AE; Fitzsimmons D; Harris S; Montgomery AA; das Nair R
    Health Technol Assess; 2020 Jan; 24(4):1-182. PubMed ID: 31934845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease activity impacts disability progression in primary progressive multiple sclerosis.
    Marrodan M; Bensi C; Pappolla A; Rojas JI; Gaitán MI; Ysrraelit MC; Negrotto L; Fiol MP; Patrucco L; Cristiano E; Farez MF; Correale J
    Mult Scler Relat Disord; 2020 Apr; 39():101892. PubMed ID: 31846866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world challenges in the diagnosis of primary progressive multiple sclerosis.
    Blok KM; Smolders J; van Rosmalen J; Martins Jarnalo CO; Wokke B; de Beukelaar J
    Eur J Neurol; 2023 Dec; 30(12):3799-3808. PubMed ID: 37578087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K
    Mult Scler; 2019 Jun; 25(7):947-957. PubMed ID: 29781383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA.
    Ziemssen T; Hoffmann O; Klotz L; Schreiber H; Weber MS; Rauser B
    JMIR Res Protoc; 2020 Jul; 9(7):e19598. PubMed ID: 32499214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary Progressive Multiple Sclerosis-A Key to Understanding and Managing Disease Progression.
    Sempik I; Dziadkowiak E; Moreira H; Zimny A; Pokryszko-Dragan A
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.